Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma

Annals of Oncology : Official Journal of the European Society for Medical Oncology
S A GrafAjay K Gopal

Abstract

High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after ASCT for MCL improves progression-free survival (PFS). The maturation of these data and any benefit of MR on overall survival (OS) remain to be defined. In this retrospective study, we examined a cohort of consecutive patients with MCL that underwent ASCT for MCL at our center and evaluated their outcomes according to whether they received MR after ASCT (n = 50) or did not (n = 107). MR was treated as a time-dependent covariate to account for variation in timing of its initiation. MR was associated with an improved PFS [hazard ratio (HR) 0.44; confidence interval (CI) (0.24-0.80), P = 0.007] and overall survival (OS; HR 0.46; CI 0.23-0.93, P = 0.03) following a multivariate adjustment for confounding factors with a median follow-up of ∼5 years. Grade 4 neutropenia was increased (34% versus 18%, P = 0.04) in the MR group, but no effect on the rate of mortality unrelated to relapse was observed. These data support that MR after ASCT for MCL confe...Continue Reading

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jun 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B S KahlUNKNOWN Wisconsin Oncology Network
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Oct 27, 2007·Blood·Eva HosterUNKNOWN European Mantle Cell Lymphoma Network
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annina HerrmannMartin Dreyling
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Niels S AndersenChristian H Geisler
Jul 26, 2011·Seminars in Hematology·Hanneke C Kluin-Nelemans, Jeanette K Doorduijn
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Nov 10, 2012·Journal of the National Comprehensive Cancer Network : JNCCN·Nicolas C Issa, Lindsey R Baden
May 27, 2014·American Society of Clinical Oncology Educational Book·Martin Dreyling, UNKNOWN European Mantle Cell Lymphoma Network
Aug 19, 2014·Hematology·Yasuyuki AraiAkifumi Takaori-Kondo
Sep 2, 2014·Haematologica·Julio DelgadoCiril Rozman

❮ Previous
Next ❯

Citations

Dec 23, 2015·Expert Review of Hematology·Layal El HalabiVincent Ribrag
Jul 24, 2018·American Journal of Hematology·Talal HilalTania Jain
Sep 11, 2019·International Journal of Molecular Sciences·Pavel Klener
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Jonathon B CohenBrad S Kahl
Oct 3, 2017·Bone Marrow Transplantation·P A Riedell, M R Bishop
Jan 4, 2017·Journal of the National Cancer Institute·Stephen E SpurgeonMitchell R Smith
Jul 23, 2018·Current Treatment Options in Oncology·Brian G Till
May 6, 2020·Drugs & Aging·Jason T Romancik, Jonathon B Cohen
Aug 28, 2021·Transplantation and Cellular Therapy·Peter A RiedellSonali M Smith
Jul 25, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Matthew G MeiLihua E Budde
Sep 25, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tobias Roider, Sascha Dietrich
Nov 16, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Andrew D ZelenetzHema Sundar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.